MSA
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🍃 Esg
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual capital growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
0
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Mysale Group PLC
📈 Performance
Price History
N/A
1M
All Time
Graph
Table
Performance graph isn't available yet for this share
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in MSA
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in MSA
N/A
MSA investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in MSA also invest in...
Want more shares? Try these...
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. The company is headquartered in Melbourne, Victoria and currently employs 77 full-time employees. The company went IPO on 2004-12-16. The Company’s Remestemcel-L is mesenchymal lineage stromal cell product platform and is in late-stage development for treatment of systemic inflammatory diseases, including Pediatric steroid refractory acute Graft versus Host Disease (SR-aGVHD), acute respiratory distress syndrome (ARDS) and Biologic refractory inflammatory bowel disease. Its Rexlemestrocel-L is mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of advanced chronic heart failure (CHF) and chronic low back pain (CLBP) due to degenerative disc disease. Two products are commercialized in Japan and Europe by the Company’s licensees, and it has a commercial partnership in Europe and China for certain Phase III assets.
📊 Share price
$1.07 AUD
Mont Royal Resources Ltd. engages in the acquisition, exploration, and development of mineral resource projects. The company is headquartered in Sydney, New South Wales. The company went IPO on 2019-05-07. The Company’s projects include Wapatik Gold-Copper Project and Northern Lights Projects, which include Northern Lights Assets, Focus Graphite Assets and Dios Assets. The Wapatik Gold-Copper Project consists of 220 claims totaling approximately 115 square kilometers (km2) in continuous tenure. The project is located approximately 93 kilometers (km) east of the Eastmain airport and 58 km southwest from the Eleonore Gold mine. The Northern Lights Project are situated in the Upper Eastmain Greenstone belt, approximately 300 km north-northeast of the town of Chibougamau and 56km south of Renard Diamond mine. The Northern Lights Projects hold a total land package of 536 km2 of the underexplored greenstone belt, approximately 150 km in length, up to 20 km wide and are located 316 km by road from Chibougamau, mining center with workforce and process plants.
📊 Share price